01/22/21 5:22 PMNasdaq : NVAXNovavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 VaccineNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines forRHEA-AIneutral
01/22/21 4:49 PMNasdaq : NVAXNovavax Names Madelyn Caltabiano Senior Vice President, Global Program ManagementNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn 'Lyn' Caltabiano, Ph.D. to the position of Senior Vice President,RHEA-AIneutral
01/15/21 8:00 AMNasdaq : NVAXRegulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality OfficerNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Henrietta Ukwu, M.D., FACP, FRAPS, to the position of Senior ViceRHEA-AIneutral
01/07/21 6:14 PMNasdaq : NVAXNovavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 VaccineNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developingRHEA-AIneutral
01/06/21 9:00 AMNasdaq : NVAXNovavax to Participate in Upcoming ConferencesNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax' COVID-19 vaccineRHEA-AIneutral
12/28/20 9:20 AMNasdaq : NVAXNovavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and MexicoPREVENT-19 will assess the efficacy, safety and immunogenicity of NVX-CoV2373 in the prevention of COVID-19 Trial to enroll up to 30,000 volunteers across approximately 115 sites in the U.S. and Mexico Two-thirds of enrollees to receive active vaccine GAITHERSBURG, Md., Dec. 28, 2020 (GLOBERHEA-AIneutral
12/21/20 5:42 PMNasdaq : NVAXBiopharma Executive Rick Crowley Joins Novavax as Chief Operations OfficerNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Rick Crowley to the newly created position of Executive Vice President,RHEA-AIvery positive
12/16/20 7:07 PMNasdaq : NVAXNovavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 VaccineNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, todayRHEA-AIneutral
12/09/20 8:02 AMNasdaq : NVAXNovavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of DirectorsNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Margaret G. McGlynn, R. Ph. to its board as an independent director. Ms.RHEA-AIneutral
11/30/20 6:30 AMNasdaq : NVAXNovavax Announces COVID-19 Vaccine Clinical Development ProgressNovavax, Inc. (Nasdaq: NVAX), a late-stage biotechnologyRHEA-AIvery positive
